A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma
- First Posted Date
- 2023-02-17
- Last Posted Date
- 2023-02-17
- Lead Sponsor
- Biocad
- Target Recruit Count
- 270
- Registration Number
- NCT05732805
- Locations
- 🇧🇾
Healthcare Institution "Bobruisk Interdistrict Oncological Dispensary", Babruysk, Belarus
🇧🇾Healthcare Institution "Vitebsk Regional Clinical Oncology Center", Vitebsk, Belarus
🇧🇾Health Institution "Gomel Regional Clinical Oncology Center", Gomel, Belarus
Efficacy and Safety of Divozilimab in Patients With Neuromyelitis Optica Spectrum Disorders (AQUARELLE)
- Conditions
- Interventions
- First Posted Date
- 2023-02-16
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Biocad
- Target Recruit Count
- 105
- Registration Number
- NCT05730699
- Locations
- 🇷🇺
Llc "Profimed", Barnaul, Russian Federation
🇷🇺Municipal Autonomous Healthcare Institution of the Order of the Red Banner of Labor "City Clinical Hospital No.1", Chelyabinsk, Russian Federation
🇷🇺Regional Clinical Hospital No.3, Chelyabinsk, Russian Federation
Clinical Study of Divozilimab in Patients With Systemic Scleroderma
- Conditions
- Interventions
- First Posted Date
- 2023-02-14
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Biocad
- Target Recruit Count
- 152
- Registration Number
- NCT05726630
- Locations
- 🇷🇺
Chelyabinsk Regional Clinical hospital, Chelyabinsk, Russian Federation
🇷🇺Clinical Rheumatology Hospital №25, Saint Petersburg, Russian Federation
🇷🇺North-Western state Medical University named after I.I. Mechnikov, Saint Petersburg, Russian Federation
Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis
- Conditions
- Interventions
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Biocad
- Target Recruit Count
- 250
- Registration Number
- NCT05445076
- Locations
- 🇷🇺
Clinical Rheumatology Hospital №25, Saint Petersburg, Russian Federation
🇷🇺North-Western state Medical University named after I.I. Mechnikov, Saint Petersburg, Russian Federation
Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of Single Escalating Doses of BCD-180 in Healthy Volunteers
- First Posted Date
- 2022-06-07
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Biocad
- Target Recruit Count
- 39
- Registration Number
- NCT05407779
- Locations
- 🇷🇺
X7 Clinical Research, Saint Petersburg, Russian Federation
An International, Multicenter, Randomized, Double-Blind, Double-Masked Study of the Efficacy and Safety of BCD-132 (JSC BIOCAD, Russia) Using an Active Reference Drug (Teriflunomide) for the Treatment of Patients With Multiple Sclerosis
- First Posted Date
- 2022-05-23
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Biocad
- Target Recruit Count
- 336
- Registration Number
- NCT05385744
- Locations
- 🇷🇺
State Budgetary Healthcare Institution of the Moscow Region M.F. Vladimirsky Moscow Regional Research and Clinical Institute, Moscow, Russian Federation
Clinical Study of the Safety and Immunogenicity of a Recombinant Viral Vector AAV5 (Adeno-Associated Virus Type 5 )-RBD (Receptor Binding Domain)-S Vaccine for the Prevention of Coronavirus Infection (COVID-19)
- First Posted Date
- 2021-09-08
- Last Posted Date
- 2023-01-30
- Lead Sponsor
- Biocad
- Target Recruit Count
- 50
- Registration Number
- NCT05037188
- Locations
- 🇷🇺
UNINOVA clinic, Saint Petersburg, Russian Federation
🇷🇺X7 Clinical Research, Saint Petersburg, Russian Federation
DEFENDOR: A Multicenter Prospective Observational Post-registration stuDy of Extimia® (INN: empEgfilrastim) to Evaluate Efficacy and saFEty in patieNts With soliD tumORs
- Conditions
- Interventions
- First Posted Date
- 2021-03-23
- Last Posted Date
- 2021-03-23
- Lead Sponsor
- Biocad
- Target Recruit Count
- 500
- Registration Number
- NCT04811443
- Locations
- 🇷🇺
St. Josaphat Belgorod Regional Clinical Hospital, Belgorod, Russian Federation
🇷🇺Regional Clinical Oncology Hospital, Yaroslavl, Yaroslavskaya Oblast, Russian Federation
🇷🇺State Health Institution "Voronezh Region Clinical Oncology Dispansary", Voronezh, Russian Federation
A Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19
- First Posted Date
- 2020-05-21
- Last Posted Date
- 2021-11-18
- Lead Sponsor
- Biocad
- Target Recruit Count
- 206
- Registration Number
- NCT04397562
- Locations
- 🇷🇺
Clinical Infectious Disease Hospital named after S.P. Botkin, Saint Petersburg, Russian Federation
🇷🇺Federal State Budgetary Educational Institution of Higher Education "North Ossetian State Medical Academy" of the Ministry of Health of the Russian Federation (FSBEI HE SOGMA of the Ministry of Health of Russia), Vladikavkaz, Russian Federation
🇷🇺State Budget Institution of the Republic of Dagestan "Republican Clinical Hospital", Machačkala, Russian Federation
Study of the Efficacy and Safety of BCD-089 in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2022-05-12
- Lead Sponsor
- Biocad
- Target Recruit Count
- 154
- Registration Number
- NCT04227366
- Locations
- 🇷🇺
Research Institute of Rheumotology, Moscow, Russian Federation